Combination chemotherapy in advanced gastrointestinal cancers: Ex vivo sensitivity to gemcitabine and mitomycin C

P. A. Whitehouse, S. J. Mercer, L. A. Knight, F. Di Nicolantonio, A. O'Callaghan, I. A. Cree

Research output: Contribution to journalArticlepeer-review

Abstract

Advanced or metastatic disease is common in both oesophagogastric and colorectal cancers, with poor 5-year survival despite palliative chemotherapy. We have investigated the sensitivity of gastrointestinal tumours to gemcitabine in combination with mitomycin C (GeM), using a modified ex vivo ATP-based tumour chemosensitivity assay (ATP-TCA). Tumour material from 41 colorectal and 22 oesophagogastric cancers were assessed. The GeM combination showed variable but definite activity in most of the samples tested. The results show that GeM achieves >95% inhibition at concentrations within the range achievable clinically in 60% of colorectal tumours (21 out of 35) and 38% of oesophagogastric tumours (five out of 13) tested. We did not identify any significant difference in sensitivity using concurrent or sequential exposure of tumour-derived cells to these two drugs. The results from this study suggest that GeM may be a useful combination in the treatment of advanced gastrointestinal malignancy.

Original languageEnglish
Pages (from-to)2299-2304
Number of pages6
JournalBritish Journal of Cancer
Volume89
Issue number12
DOIs
Publication statusPublished - Dec 2003

Keywords

  • ATP-TCA
  • Chemotherapy
  • Colorectal cancer
  • Gemcitabine
  • Mitomycin C
  • Oesophageal cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Combination chemotherapy in advanced gastrointestinal cancers: Ex vivo sensitivity to gemcitabine and mitomycin C'. Together they form a unique fingerprint.

Cite this